We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Patent Board Grants Inter Partes Review Of Arthritis Treatment Patent

(June 14, 2016, 1:15 PM EDT) -- ALEXANDRIA, Va. — A patented method of treating rheumatoid arthritis with anti-tumor necrosis factor α (anti-TNFα) combined with the anti-rheumatic drug methotrexate (MTX) is likely invalid, the Patent Trial and Appeal...
To view the full article, register now.